title: Outcome of allogeneic bone marrow transplantation for children with advanced acute myeloid leukemia.
abstract: Allogeneic bone marrow transplantation (BMT) may offer the only chance of cure for children with acute myeloid leukemia (AML) in second complete remission (CR2) or with relapsed disease, but the outcome of these patients has not been clearly defined. We conducted a retrospective study of 58 children, median age 7.4 years (range 0.8-17.3), who received matched related or unrelated BMT at our institution for AML in CR2 (n = 12), in untreated first relapse (n = 11) or with refractory disease (n = 35), to identify risk factors associated with disease-free survival (DFS). Life threatening to fatal regimen-related toxicity was observed in 22% of patients. Estimates of DFS at 5 years (95% confidence interval) for patients in CR2, with untreated first relapse and refractory disease were 58% (27-80%), 36% (11-63%) and 9% (2-21%), respectively. Non-relapse mortality estimates were 0%, 27% (0-54%) and 17% (5-30%), and relapse estimates were 42% (14-70%), 36% (8-65%) and 74% (60-89%), respectively. Advanced disease phase and cytogenetic abnormalities at the time of transplantation were each associated with decreased DFS and increased relapse in multivariable regression models. Survival for children transplanted in CR2 or untreated first relapse is higher than that previously reported, but relapse remains the major cause of treatment failure regardless of disease stage.
authors.affiliation: Department of Pediatrics, Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, USA. enemecek@fhcrc.org
authors.forename: E R
authors.initials: ER
authors.lastname: Nemecek
authors.forename: T A
authors.initials: TA
authors.lastname: Gooley
authors.forename: A E
authors.initials: AE
authors.lastname: Woolfrey
authors.forename: P A
authors.initials: PA
authors.lastname: Carpenter
authors.forename: D C
authors.initials: DC
authors.lastname: Matthews
authors.forename: J E
authors.initials: JE
authors.lastname: Sanders
mesh_terms: D000293:Adolescent; D016026:Bone Marrow Transplantation / Q000401:mortality / Q000502:physiology*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control; D006650:Histocompatibility Testing; D006801:Humans; D007223:Infant; D015470:Leukemia, Myeloid, Acute / Q000401:mortality / Q000628:therapy*; D008297:Male; D012008:Recurrence; D012189:Retrospective Studies; D016019:Survival Analysis; D013997:Time Factors; D014184:Transplantation, Homologous / Q000502:physiology; D016896:Treatment Outcome